Corrigendum: Eligibility for clinical trials in primary Sjögren's syndrome: Lessons from the UK Primary Sjögren's Syndrome Registry [Rheumatology, 55, (2016) (544-552)] doi:10.1093/rheumatology/kev373

Further to publication of this paper the Authors have identified that although all 688 participants had a clinical diagnosis of primary Sjögren's Syndrome and 668 (97.1%) fulfilled the American-European Consensus Group (AECG) classification criteria, 20 patients (2.9%) did not have sufficient features to do so. This error arose from an incorrect assumption derived from the database during analysis, for which the Authors apologize. There is no impact on the outcome or conclusions of the paper, but the methods have been amended accordingly online. The Authors also identified a small number of minor errors as follows: In the abstract the number eligible for the TEARS study is 46.3% not 31.6% (see Table 2). In Table 1: DMARD %=9.6; Pilocarpine or DMARD %=16.6; Unstimulated flow rate>1.5mls/15 mins %=15.0; Low C3%=2.0; Low C4%=17.2; Lymphoma %=4.8 (see supplementary table).